Adam Antflick, DO
Interventional Pain Medicine · Las Vegas, NVNPI 1114274057
Payments from drug & device makers
Across 850 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Nevro Corp.$4K
- Abbott$3K
- AbbVie$2K
- Redhill Biopharma Inc.$1K
- Boston Scientific$1K
- plus $9K from 49 others
Across 1 payment — averaging $410.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$410
What the payments were for
- Consulting fees$1,0404%
- Travel & lodging$2,3259%
- Food & beverage$22,17987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$1,575
- INTELLIS ADAPTIVESTIM$1,243
- Proclaim IPG$1,092
- MOVANTIK$1,040
- Senza$815
- ADAPTIVESTIM$812
- INCEPTIV$520
- SPECTRA WAVEWRITER$467
- Proclaim Family of SCS IPGs$463
- VANTA ADAPTIVESTIM$412
- Senza Spinal Cord Stimulation System$355
- PROCLAIM$345
- INTELLIS$282
- Senza II$281
- Intracept$172
- Accurian$165
- KYPHON EXPRESS II KYPHOPAK TRAY$144
- Evoke$137
- MYSTIM$124
- Vyrsa V1$124
How this compares
$25,544 in reported general payments places this provider in the 85th percentile of 32 interventional pain medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 329 | $83,479 |
| Xtampza ErOxycodone Myristate | 51 | $40,847 |
| UbrelvyUbrogepant | 19 | $35,132 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $16,843 |
| OxycontinOxycodone Hcl | 11 | $8,600 |
| Lidocaine | 75 | $8,448 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 327 | $7,374 |
| Oxycodone Hcl | 350 | $7,098 |
| Gabapentin | 506 | $6,009 |
| Naloxone Hcl | 81 | $5,987 |
| Morphine Sulfate ErMorphine Sulfate | 212 | $4,608 |
| Pregabalin | 198 | $3,635 |
| Tizanidine Hcl | 219 | $3,112 |
| Diclofenac Sodium | 54 | $2,411 |
| Tramadol Hcl | 142 | $2,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $345 | $40,84751 claims |
| AbbVieUbrelvy | $2,085 | $35,13219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 32 interventional pain medicine providers in Nevada.
Other interventional pain medicine in Las Vegas
- Daniel BurkheadLas Vegas$29K
- Stephen GephardtLas Vegas$14K
- Jeremy LipshutzLas Vegas$13K
- Denys GoloshchapovLas Vegas$11K
- Edson ErkulvrawatrLas Vegas$6K
- Alafuro OrueneLas Vegas$6K
- Dolue EzeanolueLas Vegas$5K
- Katherine TravnicekLas Vegas$5K
- Godwin MadukaLas Vegas$4K
- Haroon AndarLas Vegas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.